998TiP GUARDIAN-101: A first in human, tumor agnostic phase I study evaluating safety and preliminary antitumor activity of CLSP-1025, a first in class, HLA-directed T cell engager (TCE) for advanced solid tumors harboring the p53 R175H mutation.
Saved in:
| Title: | 998TiP GUARDIAN-101: A first in human, tumor agnostic phase I study evaluating safety and preliminary antitumor activity of CLSP-1025, a first in class, HLA-directed T cell engager (TCE) for advanced solid tumors harboring the p53 R175H mutation. |
|---|---|
| Authors: | Subbiah, V.1 (AUTHOR), Bashir, B.2 (AUTHOR), El-Khoueiry, A.B.3 (AUTHOR), Punekar, S.4 (AUTHOR), Khawaja, M.R.5 (AUTHOR), Gutierrez, M.6 (AUTHOR), Olszanski, A.J.7 (AUTHOR), Bilusic, M.8 (AUTHOR), Arnold, S.M.9 (AUTHOR), Scott, A.J.10 (AUTHOR), Berlin, J.D.11 (AUTHOR), Oh, D.12 (AUTHOR), Schoenfeld, A.13 (AUTHOR), Zhen, D.B.14 (AUTHOR), Liao, C-Y.A.15 (AUTHOR), Shepherd, J.16 (AUTHOR), McEachern, K.17 (AUTHOR), Harshman, L.C.16 (AUTHOR), Luke, J.J.18 (AUTHOR), Yap, T.A.19 (AUTHOR) |
| Source: | Annals of Oncology. 2025 Supplement 2, Vol. 36, pS652-S653. 2p. |
| Database: | Academic Search Ultimate |
| ISSN: | 09237534 |
|---|---|
| DOI: | 10.1016/j.annonc.2025.08.1567 |
